Charles James A, Jotkowitz Seymour, Byrd Lawrence H
New Jersey Medical School, Department of Neurosciences, Newark 07103, USA.
Headache. 2006 Mar;46(3):503-7. doi: 10.1111/j.1526-4610.2006.00382.x.
To explore the effects of olmesartan on frequency and severity of migraine attacks in patients with comorbid hypertension and prehypertension.
A randomized, double-blind, placebo-controlled, crossover study with a total of 60 patients has demonstrated the efficacy and safety of the angiotensin II receptor blocker candesartan in migraine prophylaxis. We study the potential efficacy and tolerability of olmesartan in preventing migraine in patients with hypertension and prehypertension.
DESIGN/METHODS: Twenty-four adults, aged 27 through 76, with either hypertension or prehypertension, were included in this open-label study. Participants suffered from migraines (diagnosed according to International Headache Society classifications) for at least 3 months. Patients were treated with 10 to 40 mg of olmesartan per various observational periods of at least 3 months. Frequency and severity were recorded by office visits or by telephonic interview.
Patients reported an 82.5% average reduction in the frequency of migraine attacks. Patients also experienced a 45% average reduction in the severity of migraine attacks measured on a numeric pain scale of 1 to 10. The only undesired effect was dizziness or presyncope. No serious adverse events occurred and no adverse event caused a premature termination. Two patients had no reduction in headache frequency, intensity, and blood pressure.
The favorable results and low rate of adverse effects, in this open migraine prevention study in patients with hypertension or prehypertension, are similar to results of the randomized, double-blind, placebo-controlled, crossover study in patients taking candesartan. Olmesartan shows a potential as an effective and well-tolerated migraine prophylactic agent for patients with comorbid hypertension and prehypertension.
探讨奥美沙坦对合并高血压和高血压前期患者偏头痛发作频率及严重程度的影响。
一项共纳入60例患者的随机、双盲、安慰剂对照、交叉研究已证实血管紧张素II受体阻滞剂坎地沙坦在偏头痛预防中的有效性和安全性。我们研究奥美沙坦在预防高血压和高血压前期患者偏头痛方面的潜在疗效和耐受性。
设计/方法：本开放标签研究纳入了24名年龄在27至76岁之间的患有高血压或高血压前期的成年人。参与者患有偏头痛（根据国际头痛协会分类诊断）至少3个月。在至少3个月的不同观察期内，患者接受10至40毫克奥美沙坦治疗。通过门诊就诊或电话访谈记录发作频率和严重程度。
患者报告偏头痛发作频率平均降低了82.5%。在1至10的数字疼痛量表上测量，患者偏头痛发作的严重程度也平均降低了45%。唯一的不良影响是头晕或晕厥前症状。未发生严重不良事件，也没有不良事件导致提前终止研究。两名患者的头痛频率、强度和血压没有降低。
在这项针对高血压或高血压前期患者的开放性偏头痛预防研究中，良好的结果和低不良反应发生率与服用坎地沙坦的患者的随机、双盲、安慰剂对照、交叉研究结果相似。奥美沙坦显示出作为一种对合并高血压和高血压前期患者有效且耐受性良好的偏头痛预防药物的潜力。
